药捷安康(2617.HK)尾盘拉升涨超21%，与Neurocrine达成项目合作

Core Viewpoint - The collaboration agreement between Neurocrine and the company for the development of NLRP3 inhibitors represents a significant opportunity for the company, with a total potential value of $881.5 million [1] Group 1: Agreement Details - Neurocrine has been granted exclusive rights to develop, manufacture, and commercialize the NLRP3 inhibitors outside Greater China, while the company retains these rights within Greater China [1] - The agreement includes upfront payments and potential milestone payments related to research and sales progress, enhancing the financial outlook for the company [1] Group 2: Financial Implications - The total potential value of the agreement is estimated at $881.5 million, indicating a substantial financial opportunity for the company [1] - The agreement may lead to further milestone payments as Neurocrine progresses in development and commercialization [1] Group 3: Research Collaboration - The agreement also encompasses research collaboration between the parties to further develop NLRP3-related technologies, which could enhance the company's product pipeline [1]